Angiotensin II receptor antagonist

Antagonists of angiotensin II receptors, or blockers of AT1 receptors is one of the new groups of antihypertensive drugs. It unites drugs that modulate the functioning of the renin-angiotensin-aldosterone system (RAAS) through interaction with angiotensin receptors.

The RAAS plays an important role in regulating blood pressure, the pathogenesis of hypertension and chronic heart failure (CHF), as well as a number of other diseases. The angiotensin (angio — vascular and tensio — a strain) — peptides produced in the body from angiotenzinoguena, which is a glycoprotein (ALPHA2-globulin) in blood plasma, which is synthesized in the liver. Under the influence of renin (an enzyme produced in juxtaglomerular apparatus of the kidney) polypeptide angiotensinogen non-Pressor activity, hydrolyses, forming angiotensin I is a biologically inactive Decapeptide, who are easily exposed to the further transformations. Under the action of angiotensin converting enzyme (ACE) produced in lungs, angiotensin I is converted into the octapeptide — angiotensin II, a highly active endogenous pressory connection.

Angiotensin II is the main effector peptide of the RAAS. He has a strong vasoconstrictor effect, increases in systemic vascular resistance, causes a rapid increase in blood pressure. In addition, it stimulates secretion of aldosterone, and in large concentrations — increases secretion of antidiuretic hormone (increased reabsorption of sodium and water, hypervolemia) and causes sympathetic activation. All of these effects contribute to the development of hypertension.

Showing 1 to 12 of 57 (5 Pages)